MedImmune, LLC - Product Pipeline Review - 2014

Published: Jan, 2014 | Pages: 106 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Summary

Global Market Direct's pharmaceuticals report, "MedImmune, LLC - Product Pipeline Review - 2014" provides data on the MedImmune, LLC's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, MedImmune, LLC's corporate website, SEC filings, investor presentations and featured press releases, both from MedImmune, LLC and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- MedImmune, LLC - Brief MedImmune, LLC overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of MedImmune, LLC human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of MedImmune, LLC with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the MedImmune, LLC's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate MedImmune, LLC's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of MedImmune, LLC in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the MedImmune, LLC's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with MedImmune, LLC.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of MedImmune, LLC and identify potential opportunities in those areas.

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
MedImmune, LLC Snapshot 6
MedImmune, LLC Overview 6
Key Information 6
Key Facts 6
MedImmune, LLC - Research and Development Overview 7
Key Therapeutic Areas 7
MedImmune, LLC - Pipeline Review 12
Pipeline Products by Stage of Development 12
Pipeline Products - Monotherapy 13
Pipeline Products - Partnered Products 14
Pipeline Products - Out-Licensed Products 16
MedImmune, LLC - Pipeline Products Glance 18
MedImmune, LLC - Late Stage Pipeline Products 18
MedImmune, LLC - Clinical Stage Pipeline Products 19
MedImmune, LLC - Early Stage Pipeline Products 21
MedImmune, LLC - Unknown Stage Pipeline Products 24
MedImmune, LLC - Drug Profiles 25
benralizumab 25
moxetumomab pasudotox 27
AMG-108 29
anifrolumab 31
dusigitumab 32
mavrilimumab 34
MEDI-551 36
sifalimumab 38
tovetumab 40
tralokinumab 41
tremelimumab 42
MEDI-4736 44
MEDI-559 45
ACP-501 46
MEDI-0639 48
MEDI-2338 49
MEDI-3617 50
MEDI-550 52
MT-111 53
Vaccines for Viral Infection 55
Antibody For Respiratory Syncytial Virus 56
Antibody Targeting ILT7 57
Drug 1 For Cancer 58
Drug 2 For Cancer 59
Drug For CV/MD 60
Drug For Neuroscience 61
Drug For Respiratory, Inflammation And Autoimmune Disorders 1 62
Drug For Respiratory, Inflammation And Autoimmune Disorders 2 63
EVT-770 64
MEDI-3379 65
Monoclonal Antibody Targeting OX40 Ligand 66
PRO-391 67
Vaccines For Infectious Disease 2 68
Vaccines For Infectious Disease 3 69
Drug 3 For Cancer 70
Drug For CV/MD 1 71
Drug For Neuroscience 1 72
Drug For Respiratory, Inflammation And Autoimmune Disorders 73
Recombinant Proteins to Activate CD3 for Cancer 74
Vaccines For Infectious Disease 1 75
MedImmune, LLC - Pipeline Analysis 76
MedImmune, LLC - Pipeline Products by Therapeutic Class 76
MedImmune, LLC - Pipeline Products by Target 79
MedImmune, LLC - Pipeline Products by Route of Administration 81
MedImmune, LLC - Pipeline Products by Molecule Type 82
MedImmune, LLC - Pipeline Products by Mechanism of Action 84
MedImmune, LLC - Recent Pipeline Updates 86
MedImmune, LLC - Dormant Projects 92
MedImmune, LLC - Discontinued Pipeline Products 94
Discontinued Pipeline Product Profiles 94
MedImmune, LLC - Company Statement 97
MedImmune, LLC - Locations And Subsidiaries 99
Head Office 99
Other Locations & Subsidiaries 99
MedImmune, LLC - Key Manufacturing Facilities 101
Appendix 102
Methodology 102
Coverage 102
Secondary Research 102
Primary Research 102
Expert Panel Validation 102
Contact Us 103
Disclaimer 103

List of Tables
MedImmune, LLC, Key Information 9
MedImmune, LLC, Key Facts 9
MedImmune, LLC - Pipeline by Indication, 2014 11
MedImmune, LLC - Pipeline by Stage of Development, 2014 15
MedImmune, LLC - Monotherapy Products in Pipeline, 2014 16
MedImmune, LLC - Partnered Products in Pipeline, 2014 17
MedImmune, LLC - Partnered Products/ Combination Treatment Modalities, 2014 18
MedImmune, LLC - Out-Licensed Products in Pipeline, 2014 19
MedImmune, LLC - Out-Licensed Products/ Combination Treatment Modalities, 2014 20
MedImmune, LLC - Phase III, 2014 21
MedImmune, LLC - Phase II, 2014 22
MedImmune, LLC - Phase I, 2014 23
MedImmune, LLC - IND/CTA Filed, 2014 24
MedImmune, LLC - Preclinical, 2014 25
MedImmune, LLC - Discovery, 2014 26
MedImmune, LLC - Unknown, 2014 27
MedImmune, LLC - Pipeline by Therapeutic Class, 2014 80
MedImmune, LLC - Pipeline by Target, 2014 83
MedImmune, LLC - Pipeline by Route of Administration, 2014 84
MedImmune, LLC - Pipeline by Molecule Type, 2014 86
MedImmune, LLC - Pipeline Products by Mechanism of Action, 2014 88
MedImmune, LLC - Recent Pipeline Updates, 2014 89
MedImmune, LLC - Dormant Developmental Projects,2014 95
MedImmune, LLC - Discontinued Pipeline Products, 2014 97
MedImmune, LLC, Other Locations 102
MedImmune, LLC, Subsidiaries 103
MedImmune, LLC, Key Manufacturing Facilities 104